Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301

作者：S. Aleman, M. Brunetto, Antje Blank, Pietro Andreoné, P. Bogomolov, V. Chulanov, N. Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, T. Stepanova, Grace M. Chee, R.C. Mercier, Andrew H. Lichtman, D. Manuilov, Sarah Arterburn, Audrey Lau, Anu Osinusi, Flo. Christian-Cox, Franck Le Duff, J.S. zur Wiesch, M. Cornberg, S. Zeuzem, H. Wedemeyer, P. Lampertico · 发表于：Digestive and Liver Disease · 年份：2025 · DOI：10.1016/j.dld.2025.01.109 · 被引用次数：1 · 研究领域：Hepatitis B Virus Studies、Hepatitis C virus research、Cytomegalovirus and herpesvirus research